Psoriasis is frequently associated with non-communicable disease (NCD) comorbidities, prompting interest in how these concurrent conditions may influence psoriasis treatment outcomes.
Objectives
To assess NCD prevalence and their influence on psoriasis treatment outcomes.
Methods
From 2022 to 2024, we recruited psoriasis patients in Shanghai Skin Disease Hospital. Data on demographic features, NCD comorbidities and treatment outcomes at week 4 and week 8 were systematically collected through questionnaire, physical examination, and clinical severity assessment (psoriasis area and severity index [PASI], body surface area [BSA], physician's global assessment [PGA]).
Results
Among 1116 patients, 48.4% had at least one NCD comorbidity. NCD-free patients exhibited higher PASI50 response rates at both week 4 (46.5 vs. 39.1%) and week 8 (72.2 vs. 70.9%). Log binomial regression revealed that NCDs significantly reduced the likelihood of achieving PASI50 at week 4 (relative risk [RR] = 0.84, 95% confidence interval [CI]: 0.73-0.96), with a similar but non-significant trend at week 8 (RR = 0.98, 95% CI: 0.92-1.06).
Conclusion
NCDs negatively impact early treatment outcomes in psoriasis patients. So we propose that dermatologists should integrate systematic NCD management into psoriasis treatment regimen.
